WO2006105146A2 - Devices, systems, methods and tools for continuous glucose monitoring - Google Patents

Devices, systems, methods and tools for continuous glucose monitoring Download PDF

Info

Publication number
WO2006105146A2
WO2006105146A2 PCT/US2006/011382 US2006011382W WO2006105146A2 WO 2006105146 A2 WO2006105146 A2 WO 2006105146A2 US 2006011382 W US2006011382 W US 2006011382W WO 2006105146 A2 WO2006105146 A2 WO 2006105146A2
Authority
WO
WIPO (PCT)
Prior art keywords
glucose
sensing
fluid
housing
sensor
Prior art date
Application number
PCT/US2006/011382
Other languages
French (fr)
Other versions
WO2006105146A3 (en
Inventor
Arvind N. Jina
Original Assignee
Arkal Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkal Medical, Inc. filed Critical Arkal Medical, Inc.
Priority to EP06748841A priority Critical patent/EP1869414A4/en
Priority to CA002602259A priority patent/CA2602259A1/en
Publication of WO2006105146A2 publication Critical patent/WO2006105146A2/en
Publication of WO2006105146A3 publication Critical patent/WO2006105146A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A61B5/14865Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors

Definitions

  • the invention relates to systems, devices, and tools, and the use of such systems, devices and tools for monitoring blood glucose levels in a person having diabetes. More specifically, the invention relates to systems, devices, and tools and the use of such systems, devices and tools for monitoring blood glucose level continuously, or substantially continuously.
  • Diabetes is a chronic, life-threatening disease for which there is no known cure. It is a syndrome characterized by hyperglycemia and relative insulin deficiency. Diabetes affects more than 120 million people world wide, and is projected to affect more than 220 million people by the year 2020. It is estimated that 1 in 3 children today will develop diabetes sometime during their lifetime. Diabetes is usually irreversible, and can lead to a variety of severe health complications, including coronary artery disease, peripheral vascular disease, blindness and stroke. The Center for Disease Control (CDC) has reported that there is a strong association between being overweight, obesity, diabetes, high blood pressure, high cholesterol, asthma and arthritis. Individuals with a body mass index of 40 or higher are more than 7 times more likely to be diagnosed with diabetes.
  • CDC Center for Disease Control
  • Type I diabetes insulin-dependent diabetes mellitus
  • Type II diabetes non-insulin-dependent diabetes mellitus
  • Varying degrees of insulin secretory failure may be present in both forms of diabetes.
  • diabetes is also characterized by insulin resistance. Insulin is the key hormone used in the storage and release of energy from food.
  • Insulin secretion functions to control the level of blood glucose both during fasting and after a meal, to keep the glucose levels at an optimum level.
  • blood glucose levels are between 80 and 90 mg/dL of blood during fasting and between 120 to 140 mg/dL during the first hour or so following a meal.
  • the insulin response does not function properly (either due to inadequate levels of insulin production or insulin resistance), resulting in blood glucose levels below 80 mg/dL during fasting and well above 140 mg/dL after a meal.
  • the blood glucose self-monitoring market is the largest self-test market for medical diagnostic products in the world, with a size of approximately $3 billion in the United States and $5.0 billion worldwide. It is estimated that the worldwide blood glucose self-monitoring market will amount to $8.0 billion by 2006. Failure to manage the disease properly has dire consequences for diabetics. The direct and indirect costs of diabetes exceed $130 billion annually in the United States - about 20% of all healthcare costs.
  • Continuous monitoring sensors are generally implanted subcutaneously and measure glucose levels in the interstitial fluid at various periods throughout the day, providing data that shows trends in glucose measurements over a short period of time. These sensors are painful during insertion and usually require the assistance of a health care professional. Further, these sensors are intended for use during only a short duration (e.g., monitoring for a matter of days to determine a blood sugar pattern). Subcutaneously implanted sensors also frequently lead to infection and immune response complications. Another major drawback of currently available continuous monitoring devices is that they require frequent, often daily, calibration using blood glucose results that must be obtained from painful finger-sticks using traditional meters and test strips.
  • the sensor is required to be implanted by a physician, and the results of the data aggregated by the system can only be accessed by the physician, who must extract the sensor and download the results to a personal computer for viewing using customized software.
  • the other product is a consumer product, which permits the user to download results to a personal computer using customized software.
  • a third product approved for continuous glucose monitoring is the Glucowatch® developed by Cygnus Inc., which is worn on the wrist like a watch and can take glucose readings every ten to twenty minutes for up to twelve hours at a time. It requires a warm up time of 2 to 3 hours and replacement of the sensor pads every 12 hours. Temperature and perspiration are also known to affect its accuracy.
  • the fourth approved product is a subcutaneously implantable glucose sensor developed by Dexcom, San Diego, CA (www.dexcom.com). AU of the approved devices are known to require daily, often frequent, calibrations with blood glucose values which the patient must obtain using conventional finger stick blood glucose monitors.
  • the invention is a novel continuous glucose monitor that may be periodically calibrated without using finger sticks or other invasive calibration techniques and measures glucose without extracting any interstitial fluid (or any other fluid) from the user.
  • the continuous glucose monitor may be configured to be self-calibrating.
  • One aspect of the invention provides a glucose monitor with a plurality of tissue piercing elements, each tissue piercing element having a distal opening, a proximal opening and interior space extending between the distal and proximal openings; a sensing area in fluid communication with the proximal openings of the tissue piercing elements; sensing fluid extending from the sensing area into substantially the entire interior space of the tissue piercing elements; and a glucose sensor adapted to detect a concentration of glucose in the sensing fluid within the sensing area.
  • This arrangement permits interstitial fluid glucose to diffuse from the interstitial fluid into the sensing area without extracting interstitial fluid through the distal openings of the piercing elements into the interior space.
  • the glucose monitor has a removable cover extending over the distal openings of the tissue piercing elements.
  • the glucose monitor has a display adapted to display a glucose concentration sensed by the sensor.
  • the display may be disposed within a housing separate from the sensor, with the glucose monitor further including a communicator adapted to wirelessly communicate sensor information from the sensor to the display.
  • the glucose monitor includes a sensing fluid reservoir and a pump adapted to move sensing fluid out of the sensing fluid reservoir into the sensing area.
  • Such embodiments may have a manual actuator and may have a waste reservoir adapted to receive sensing fluid from the sensing area.
  • the glucose monitor may have a housing with a first part and a second part, the first part of the housing being adapted to support the tissue piercing elements, the sensing fluid reservoir, the sensing area, and at least part of the sensor, the second part of the housing having an electrical connection to the at least part of the sensor in the first part of the housing, with the housing further including a connector adapted to connect and disconnect the first part of the housing from the second part of the housing.
  • the first part of the housing is further adapted to support the pump and optionally the waste reservoir.
  • Some embodiments have a communicator supported by the second part of the housing and adapted to communicate sensor information to a display.
  • the sensing fluid in the sensing fluid reservoir has a glucose concentration of between about 0 mg/dl and about 400 mg/dl.
  • the sensing fluid may also contain buffers, preservatives or other materials in addition to the glucose.
  • the glucose monitor has an adhesive element adjacent the tissue piercing elements and adapted to attach to a user's skin.
  • the glucose sensor, tissue piercing elements and sensing area may be further adapted to detect a concentration of glucose in the sensing fluid within the sensing area without extracting interstitial fluid through the distal openings into the interior space.
  • Another aspect of the invention provides a method of in vivo monitoring of an individual's interstitial fluid glucose concentration including the following steps: inserting distal ends of a plurality of tissue piercing elements through a stratum corneum area of the individual's skin, the tissue piercing elements each having a distal opening, a proximal opening, an interior space extending between the distal and proximal openings, and a sensing fluid filling substantially the entire interior space; and sensing a glucose concentration of the sensing fluid.
  • This method permits interstitial fluid glucose to diffuse from the interstitial fluid into the sensing area without extracting interstitial fluid through the distal openings of the piercing elements into the interior space.
  • Some embodiments include the step of removing a cover from the distal openings of the tissue piercing elements prior to the inserting step.
  • Some embodiments include the step of displaying glucose concentration information remote from the stratum corneum area of the individual's skin. The method may also include the step of wirelessly communicating glucose concentration information to a display.
  • the sensing step is performed by a sensor in fluid communication with a sensing area and the interior spaces of the tissue piercing elements, and the method further includes the step of calibrating the sensor by moving sensing fluid into the sensing area, such as by using a pump.
  • the method may also include the step of moving sensing fluid out of the sensing area as sensing fluid is moved into the sensing area.
  • the sensing fluid may have a glucose concentration of between about 0 mg/dl and about 400 mg/dl.
  • the step of moving sensing fluid includes the steps of moving sensing fluid from a sensing fluid reservoir
  • the sensing fluid reservoir, sensing area, tissue piercing elements and at least part of the sensor may be supported by a first part of a housing
  • the method further includes the step of attaching the first part of the housing to a second part of the housing prior to the inserting step, with the second part of the housing having an electrical connection to the at least part of the sensor in the first part of the housing.
  • the method may also include the step of separating the second part of the housing from the first part of the housing after the sensing step.
  • the method includes the step of attaching the tissue piercing elements to the individual with adhesive.
  • the method includes the step of permitting glucose to diffuse from interstitial fluid of the individual through the distal openings into the interior space.
  • Another embodiment of the invention includes a glucose monitor comprising a plurality of tissue piercing elements, each tissue piercing element comprising a distal opening, a proximal opening and an interior space extending between the distal and proximal openings; a sensing area in continuous_fluid communication with the proximal openings of the tissue piercing elements; sensing fluid extending from the sensing area into substantially the entire interior space of the tissue piercing elements; and a glucose sensor adapted to continuously detect a concentration of glucose in the sensing fluid within the sensing area further adapted to be self-calibrating.
  • Figure 1 is a cross-sectional schematic view of a glucose monitoring device according to one embodiment of the invention in place on a user's skin.
  • Figure 2 shows an exploded view of a glucose monitoring device according to another embodiment of the invention.
  • Figures 3(a) and (b) are a schematic representative drawing of a three electrode system for use with the glucose sensor of one embodiment of this invention.
  • Figures 4(a) and (b) are a schematic representative drawing of a two electrode system for use with the glucose sensor of one embodiment of this invention.
  • Figure 5 is a cross-sectional schematic view of a portion of a glucose monitoring device according to yet another embodiment of the invention.
  • Figure 6 shows a remote receiver for use with a glucose monitoring system according to yet another embodiment of the invention.
  • Figure 7 shows a glucose sensor in place on a user's skin and a remote monitor for use with the sensor.
  • the present invention provides a significant advance in biosensor and glucose monitoring technology, portable, virtually non-invasive, self-calibrating, integrated and non-implanted sensors which continuously indicate the user's blood glucose concentration, enabling swift corrective action to be taken by the patient.
  • the sensor and monitor of this invention may be used to measure other analytes as well, such as electrolytes like sodium or potassium ions.
  • the glucose sensor can be any suitable sensor including, for example, an electrochemical sensor an optical sensor.
  • FIG. 1 shows a schematic cross-section of one embodiment of the invention in use.
  • the glucose monitor 100 has an array of unique hollow microneedles 102 or other tissue piercing elements extending through the stratum corneum 104 of a user into the interstitial fluid 106 beneath the stratum corneum.
  • Suitable microneedle arrays include those described in Stoeber et al. US Patent 6,406,638; US Patent Appl. Publ. No. 2005/0171480; and US Patent Appl. Publ. No. 2006/0025717.
  • the needles in array 102 axe hollow and have open distal ends, and their interiors communicate with a sensing area 110 within a sensor channel 108.
  • Sensing area 110 is therefore in fluid communication with interstitial fluid 106 through microneedle array 102.
  • sensing area 110 and the microneedles 102 are pre-filled with sensing fluid prior to the first use of the device.
  • glucose sensor 112 Disposed above and in fluid communication with sensor channel 108 is a glucose sensor 112.
  • glucose sensor is an electrochemical glucose sensor that generates an electrical signal (current, voltage or charge) whose value depends on the concentration of glucose in the fluid within sensing area 110. Details of the operation of glucose sensor 112 are discussed in more detail below.
  • Sensor electronics element 114 receives the voltage signal from sensor 112. In some embodiments, sensor electronics element 114 uses the sensed signal to compute a glucose concentration and display it. In other embodiments, sensor electronics element 114 transmits the sensed signal, or information derived from the sensed signal, to a remote device, such as through wireless communication. Glucose monitor 100 is held in place on the skin 104 by one or more adhesive pads 116.
  • Glucose monitor 100 has a novel built-in sensor calibration system.
  • the glucose concentration in the sensing fluid is selected to be below the glucose sensing range of the sensor.
  • the sensing fluid may also contain buffers, preservatives or other components in addition to the glucose.
  • any sensing fluid within channel 108 is forced through a second check valve 124 (e.g., a flap valve) into a waste reservoir 126.
  • Check valves or similar gating systems are used to prevent contamination. Because the fresh sensing fluid has a known glucose concentration, sensor 112 can be calibrated at this value to set a base line. After calibration, the sensing fluid in channel 108 remains stationary, and glucose from the interstitial fluid 106 diffuses through microneedles 102 into the sensing area 110: Changes in the glucose concentration from over time reflect differences between the calibration glucose concentration of the sensing fluid in the reservoir 118 and the glucose concentration of the interstitial fluid which can be correlated with the actual blood glucose concentration of the user using proprietary algorithms.
  • microneedle array 102, reservoirs 118 and 126, channel 108, sensor 112 and adhesive pads 116 are contained within a support structure (such as a housing 128) separate from electronics element 114 and actuator 120, which are supported within their own housing 130. This arrangement permits the sensor, sensing fluid and microneedles to be discarded after a period of use (e.g., when reservoir 118 is depleted) while enabling the electronics and actuator to be reused.
  • a flexible covering (made, e.g., of polyester or other plastic-like material) may surround and support the disposable components.
  • the interface between actuator 120 and reservoir 118 must permit actuator 120 to move sensing fluid out of reservoir 118, such as by deforming a wall of the reservoir.
  • housings 128 and 130 may have a mechanical connection, such as a snap or interference fit.
  • Figure 2 shows an exploded view of another embodiment of the invention. This figure shows a removable seal 203 covering the sharp distal ends of microneedles 202 and attached, e.g., by adhesive. Seal 203 maintains the sensing fluid within the microneedles and sensing area prior to use and is removed prior to placing the glucose monitor 200 on the skin using adhesive pressure seal 216.
  • microneedles 202, sensing fluid and waste reservoirs 218 and 226, sensing microchannel 208 and electrochemical glucose sensor 212 are contained within and/or supported by a housing 228 which forms the disposable portion of the device.
  • a second housing 230 supports an electronics board 214 (containing, e.g., processing circuitry, a power source, transmission circuitry, etc.) and an actuator 220 that can be used to move sensing fluid out of reservoir 218, through microchannel 208 into waste reservoir 226.
  • Electrical contacts 215 extend from electronics board 214 to make contact with corresponding electrodes in glucose sensor 212 when the device is assembled.
  • Clark and Lyons proposed the first enzyme electrode (that was implemented later by Updike and Hicks) to determine glucose concentration in a sample by combining the specificity of a biological system with the simplicity and sensitivity of an electrochemical transducer.
  • the most common strategies for glucose detection are based on using either glucose oxidase or glucose dehydrogenase enzyme.
  • Electrochemical sensors for glucose based on the specific glucose oxidizing enzyme glucose oxidase, have generated considerable interest.
  • Several commercial devices based on this principle have been developed and are widely used currently for monitoring of glucose, e.g., self testing by patients at home, as well as testing in physician offices and hospitals.
  • the earliest amperometric glucose biosensors were based on glucose oxidase (GOX) which generates hydrogen peroxide in the presence of oxygen and glucose according to the following reaction scheme: Glucose + GOX-FAD (ox) -> Gluconolactone + GOX-FADH 2 (red)
  • Electrochemical biosensors are used for glucose detection because of their high sensitivity, selectivity and low cost.
  • amperometric detection is based on measuring either the oxidation or reduction of an electroactive compound at a working electrode (sensor).
  • a constant potential is applied to that working electrode with respect to another electrode used as the reference electrode.
  • the glucose oxidase enzyme is first reduced in the process but is reoxidized again to its active form by the presence of any oxygen resulting in the formation of hydrogen peroxide.
  • Glucose sensors generally have been designed by monitoring either the hydrogen peroxide formation or the oxygen consumption.
  • the hydrogen peroxide produced is easily detected at a potential of +0.6 V relative to a reference electrode such as an Ag/AgCl electrode.
  • sensors based on hydrogen peroxide detection are subject to electrochemical interference by the presence of other oxidizable species in clinical samples such as blood or serum.
  • biosensors based on oxygen consumption are affected by the variation of oxygen concentration in ambient air.
  • different strategies have been developed and adopted. [0043] Selectively permeable membranes or polymer films have been used to suppress or minimize interference from endogenous electroactive species in biological samples. Another strategy to solve these problems is to replace oxygen with electrochemical mediators to reoxidize the enzyme.
  • Mediators are electrochemically active compounds that can reoxidize the enzyme (glucose oxidase) and then be reoxidized at the working electrode as shown below: GOX-FADH 2 (red) + Mediator (ox) -> GOX-FAD (ox) + Mediator (red)
  • Electrochemical mediators act as redox couples to shuttle electrons between the enzyme and electrode surface. Because mediators can be detected at lower oxidation potentials than that used for the detection of hydrogen peroxide the interference from electroactive species (e.g., ascorbic and uric acids present) in clinical samples such as blood or serum is greatly reduced.
  • electroactive species e.g., ascorbic and uric acids present
  • ferrocene derivatives have oxidation potentials in the +0.1 to 0.4 V range.
  • Conductive organic salts such as tetrathiafulvalene- tetracyanoquinodimethane (TTF-TCNQ) can operate as low as 0.0 Volts relative to a Ag/AgCl reference electrode.
  • a working electrode 302 is referenced against a reference electrode 304 (such as Ag/AgCl) and a counter electrode 306 (such as Pt) provides a means for current flow.
  • the three electrodes are mounted on a substrate 308, then covered with a reagent 310, as shown in Figure 3(b).
  • Figure 4 shows a two electrode system, wherein the working and counter electrodes 402 and 404 are made of different electrically conducting materials.
  • the electrodes 402 and 404 are mounted on a flexible substrate 408 as shown in Figure 4(a) and covered with a reagent 410, as shown in Figure 4(b).
  • the working and counter electrodes are made of the same electrically conducting materials, where the reagent exposed surface area of the counter electrode is slightly larger than that of the working electrode or where both the working and counter electrodes are substantially of equal dimensions. [0047] In amperometric and coulometric biosensors, immobilization of the enzymes is also very important.
  • enzyme immobilization include covalent binding, physical adsorption or cross-linking to a suitable matrix may be used.
  • the reagent is contained in a reagent well in the biosensor.
  • the reagent includes a redox mediator, an enzyme, and a buffer, and covers substantially equal surface areas of portions of the working and counter electrodes.
  • a sample containing the analyte to be measured in this case glucose
  • the analyte comes into contact with the glucose biosensor the analyte is oxidized, and simultaneously the mediator is reduced.
  • an electrical potential difference is applied between the electrodes.
  • the amount of oxidized form of the redox mediator at the counter electrode and the applied potential difference must be sufficient to cause diffusion limited electrooxidation of the reduced form of the redox mediator at the surface of the working electrode.
  • the current produced by the electrooxidation of the reduced form of the redox mediator is measured and correlated to the amount of the analyte concentration in the sample.
  • the analyte sought to be measured may be reduced and the redox mediator may be oxidized.
  • these requirements are satisfied by employing a readily reversible redox mediator and using a reagent with the oxidized form of the redox mediator in an amount sufficient to insure that the diffusion current produced is limited by the oxidation of the reduced form of the redox mediator at the working electrode surface.
  • the amount of the oxidized form of the redox mediator at the surface of the counter electrode must always exceed the amount of the reduced form of the redox mediator at the surface of the working electrode.
  • the working and counter electrodes may be substantially the same size or unequal size as well as made of the same or different electrically conducting material or different conducting materials. From a cost perspective the ability to utilize electrodes that are fabricated from substantially the same material represents an important advantage for inexpensive biosensors.
  • the redox mediator must be readily reversible, and the oxidized form of the redox mediator must be of sufficient type to receive at least one electron from the reaction involving enzyme, analyte, and oxidized form of the redox mediator.
  • enzymes and redox mediators that may be used in measuring particular analytes by the present invention are ferrocene and or ferrocene derivative, ferricyanide, and viologens. Buffers may be used to provide a preferred pH range from about 4 to 8.
  • the most preferred pH range is from about 6 to 7.
  • the most preferred buffer is phosphate (e.g., potassium phosphate) from about 0. IM to 0.5M and preferably about 0.4M. (These concentration ranges refer to the reagent composition before it is dried onto the electrode surfaces.) More details regarding glucose sensor chemistry and operation may be found in: Clark LC. and Lyons C. "Electrode Systems for Continuous Monitoring in Cardiovascular Surgery," Ann NY Acad Sci, 102:29, 1962; Updike SJ, and Hicks GP. "The Enzyme Electrode,” Nature, 214:986, 1967; Cass, A.E. G., G. Davis. G.D. Francis, et. al. 1984.
  • Ferrocene -mediated enzyme electrode for amperometric determination of glucose.
  • FIG. 5 Another embodiment of the disposable portion of the glucose monitor invention is shown in Figure 5 with a microneedle array 502 and a glucose sensor 512 in fluid communication with a sensing area in channel 508.
  • actuator 520 is on the side of sensing fluid reservoir 518, and the waste reservoir 526 is expandable. Operation of actuator 520 sends sensing fluid from reservoir 518 through one way flap valve 522 into the sensing area in channel 508 and forces sensing fluid within channel 508 through flap valve 524 into the expandable waste reservoir 526.
  • the starting amount of sensing fluid in the calibration reservoir 518 is about 1.0 ml or less, and operation of the sensing fluid actuator 520 sends a few microliters (e.g., 10 ⁇ L) of sensing fluid into channel 508. Recalibrating the device three times a day for seven days will use less than 250 ⁇ L of sensing fluid.
  • FIGS 6 and 7 show a remote receiver for use with a glucose monitoring system.
  • the wireless receiver can be configured to be worn by a patient on a belt, or carried in a pocket or purse.
  • glucose sensor information is transmitted by the glucose sensor 602 applied to the user's skin to receiver 600 using, e.g., wireless communication such as radio frequency (RF) or Bluetooth wireless.
  • RF radio frequency
  • the receiver may maintain a continuous link with the sensor, or it may periodically receive information from the sensor.
  • the sensor and its receiver may be synchronized using RFID technology or other unique identifiers.
  • Receiver 600 may be provided with a display 604 and user controls 606.
  • the display may show, e.g., glucose values, directional glucose trend arrows and rates of change of glucose concentration.
  • the receiver can also be configured with a speaker adapted to deliver an audible alarm, such as high and low glucose alarms. Additionally, the receiver can include a memory device, such as a chip, that is capable of storing glucose data for analysis by the user or by a health care provider.
  • the source reservoir for the calibration and sensing fluid may be in a blister pack which maintains its integrity until punctured or broken.
  • the actuator may be a small syringe or pump. Use of the actuator for recalibration of the sensor may be performed manually by the user or may be performed automatically by the device if programmed accordingly. There may also be a spring or other loading mechanism within the reusable housing that can be activated to push the disposable portion — and specifically the microneedles — downward into the user's skin.

Abstract

One aspect of the invention provides a glucose monitor having a plurality of tissue piercing elements each tissue piercing element having a distal opening, a proximal opening and interior space extending between the distal and proximal opening, a sensing area in fluid communication with the proximal opening of the tissue piercing elements, sensing fluid extending from the sensing area into substantially the entire interior space of the tissue piercing elements, and a glucose sensor adapted to detect a concentration of glucose in the sensing fluid within the sensing area. Another aspect of the invention provides a method of in vivo monitoring an individual's interstitial fluid glucose concentration using such a glucose monitor.

Description

DEVICES, SYSTEMS, METHODS AND TOOLS FOR CONTINUOUS GLUCOSE MONITORING
CROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 60/666,775, filed March 29, 2005, and U.S. Provisional Application No. 60/743,080, filed December 27, 2005, which are incorporated herein by reference in their entirety.
BACKGROUND OF THE INVENTION
[0002] The invention relates to systems, devices, and tools, and the use of such systems, devices and tools for monitoring blood glucose levels in a person having diabetes. More specifically, the invention relates to systems, devices, and tools and the use of such systems, devices and tools for monitoring blood glucose level continuously, or substantially continuously.
[0003] Diabetes is a chronic, life-threatening disease for which there is no known cure. It is a syndrome characterized by hyperglycemia and relative insulin deficiency. Diabetes affects more than 120 million people world wide, and is projected to affect more than 220 million people by the year 2020. It is estimated that 1 in 3 children today will develop diabetes sometime during their lifetime. Diabetes is usually irreversible, and can lead to a variety of severe health complications, including coronary artery disease, peripheral vascular disease, blindness and stroke. The Center for Disease Control (CDC) has reported that there is a strong association between being overweight, obesity, diabetes, high blood pressure, high cholesterol, asthma and arthritis. Individuals with a body mass index of 40 or higher are more than 7 times more likely to be diagnosed with diabetes. [0004] There are two main types of diabetes, Type I diabetes (insulin-dependent diabetes mellitus) and Type II diabetes (non-insulin-dependent diabetes mellitus). Varying degrees of insulin secretory failure may be present in both forms of diabetes. In some instances, diabetes is also characterized by insulin resistance. Insulin is the key hormone used in the storage and release of energy from food.
[0005] As food is digested, carbohydrates are converted to glucose and glucose is absorbed into the blood stream primarily in the intestines. Excess glucose in the blood, e.g. following a meal, stimulates insulin secretion, which promotes entry of glucose into the cells, which controls the rate of metabolism of most carbohydrates.
[0006] Insulin secretion functions to control the level of blood glucose both during fasting and after a meal, to keep the glucose levels at an optimum level. In a normal person blood glucose levels are between 80 and 90 mg/dL of blood during fasting and between 120 to 140 mg/dL during the first hour or so following a meal. For a person with diabetes, the insulin response does not function properly (either due to inadequate levels of insulin production or insulin resistance), resulting in blood glucose levels below 80 mg/dL during fasting and well above 140 mg/dL after a meal.
[0007] Currently, persons suffering from diabetes have limited options for treatment, including taking insulin orally or by injection. In some instances, controlling weight and diet can impact the amount of insulin required, particularly for non-insulin dependent diabetics. Monitoring blood glucose levels is an important process that is used to help diabetics maintain blood glucose levels as near as normal as possible throughout the day.
[0008] The blood glucose self-monitoring market is the largest self-test market for medical diagnostic products in the world, with a size of approximately $3 billion in the United States and $5.0 billion worldwide. It is estimated that the worldwide blood glucose self-monitoring market will amount to $8.0 billion by 2006. Failure to manage the disease properly has dire consequences for diabetics. The direct and indirect costs of diabetes exceed $130 billion annually in the United States - about 20% of all healthcare costs. [0009] There are two main types of blood glucose monitoring systems used by patients: single point or non- continuous and continuous. Non-continuous systems consist of meters and tests strips and require blood samples to be drawn from fingertips or alternate sites, such as forearms and legs (e.g. OneTouch® Ultra by LifeScan, Inc., Milpitas, CA, a Johnson & Johnson company). These systems rely on lancing and manipulation of the fingers or alternate blood draw sites, which can be extremely painful and inconvenient, particularly for children.
[0010] Continuous monitoring sensors are generally implanted subcutaneously and measure glucose levels in the interstitial fluid at various periods throughout the day, providing data that shows trends in glucose measurements over a short period of time. These sensors are painful during insertion and usually require the assistance of a health care professional. Further, these sensors are intended for use during only a short duration (e.g., monitoring for a matter of days to determine a blood sugar pattern). Subcutaneously implanted sensors also frequently lead to infection and immune response complications. Another major drawback of currently available continuous monitoring devices is that they require frequent, often daily, calibration using blood glucose results that must be obtained from painful finger-sticks using traditional meters and test strips. This calibration, and re-calibration, is required to maintain sensor accuracy and sensitivity, but it can be cumbersome as well as painful. [0011] At tin's time, there are four products approved by the FDA for continuous glucose monitoring, none of which are presently approved as substitutes for current glucose self-monitoring devices. Medtronic (www.medtronic) has two continuous glucose monitoring products approved for sale: Guardian® RT Real-Time Glucose Monitoring System and CGMS® System. Each product includes an implantable sensor that measures and stores glucose values for a period of up to three days. One product is a physician product. The sensor is required to be implanted by a physician, and the results of the data aggregated by the system can only be accessed by the physician, who must extract the sensor and download the results to a personal computer for viewing using customized software. The other product is a consumer product, which permits the user to download results to a personal computer using customized software. [0012] A third product approved for continuous glucose monitoring is the Glucowatch® developed by Cygnus Inc., which is worn on the wrist like a watch and can take glucose readings every ten to twenty minutes for up to twelve hours at a time. It requires a warm up time of 2 to 3 hours and replacement of the sensor pads every 12 hours. Temperature and perspiration are also known to affect its accuracy. The fourth approved product is a subcutaneously implantable glucose sensor developed by Dexcom, San Diego, CA (www.dexcom.com). AU of the approved devices are known to require daily, often frequent, calibrations with blood glucose values which the patient must obtain using conventional finger stick blood glucose monitors.
SUMMARY OF THE INVENTION
[0013] The invention is a novel continuous glucose monitor that may be periodically calibrated without using finger sticks or other invasive calibration techniques and measures glucose without extracting any interstitial fluid (or any other fluid) from the user. The continuous glucose monitor may be configured to be self-calibrating. [0014] One aspect of the invention provides a glucose monitor with a plurality of tissue piercing elements, each tissue piercing element having a distal opening, a proximal opening and interior space extending between the distal and proximal openings; a sensing area in fluid communication with the proximal openings of the tissue piercing elements; sensing fluid extending from the sensing area into substantially the entire interior space of the tissue piercing elements; and a glucose sensor adapted to detect a concentration of glucose in the sensing fluid within the sensing area. This arrangement permits interstitial fluid glucose to diffuse from the interstitial fluid into the sensing area without extracting interstitial fluid through the distal openings of the piercing elements into the interior space. In some embodiments, the glucose monitor has a removable cover extending over the distal openings of the tissue piercing elements.
[0015] In some embodiments, the glucose monitor has a display adapted to display a glucose concentration sensed by the sensor. The display may be disposed within a housing separate from the sensor, with the glucose monitor further including a communicator adapted to wirelessly communicate sensor information from the sensor to the display.
[0016] In some embodiments, the glucose monitor includes a sensing fluid reservoir and a pump adapted to move sensing fluid out of the sensing fluid reservoir into the sensing area. Such embodiments may have a manual actuator and may have a waste reservoir adapted to receive sensing fluid from the sensing area. In some such embodiments, the glucose monitor may have a housing with a first part and a second part, the first part of the housing being adapted to support the tissue piercing elements, the sensing fluid reservoir, the sensing area, and at least part of the sensor, the second part of the housing having an electrical connection to the at least part of the sensor in the first part of the housing, with the housing further including a connector adapted to connect and disconnect the first part of the housing from the second part of the housing. In some embodiments, the first part of the housing is further adapted to support the pump and optionally the waste reservoir. Some embodiments have a communicator supported by the second part of the housing and adapted to communicate sensor information to a display. [0017] In some embodiments, the sensing fluid in the sensing fluid reservoir has a glucose concentration of between about 0 mg/dl and about 400 mg/dl. The sensing fluid may also contain buffers, preservatives or other materials in addition to the glucose. In yet other embodiments, the glucose monitor has an adhesive element adjacent the tissue piercing elements and adapted to attach to a user's skin. The glucose sensor, tissue piercing elements and sensing area may be further adapted to detect a concentration of glucose in the sensing fluid within the sensing area without extracting interstitial fluid through the distal openings into the interior space. [0018] Another aspect of the invention provides a method of in vivo monitoring of an individual's interstitial fluid glucose concentration including the following steps: inserting distal ends of a plurality of tissue piercing elements through a stratum corneum area of the individual's skin, the tissue piercing elements each having a distal opening, a proximal opening, an interior space extending between the distal and proximal openings, and a sensing fluid filling substantially the entire interior space; and sensing a glucose concentration of the sensing fluid. This method permits interstitial fluid glucose to diffuse from the interstitial fluid into the sensing area without extracting interstitial fluid through the distal openings of the piercing elements into the interior space. Some embodiments include the step of removing a cover from the distal openings of the tissue piercing elements prior to the inserting step. Some embodiments include the step of displaying glucose concentration information remote from the stratum corneum area of the individual's skin. The method may also include the step of wirelessly communicating glucose concentration information to a display. [0019] In some embodiments, the sensing step is performed by a sensor in fluid communication with a sensing area and the interior spaces of the tissue piercing elements, and the method further includes the step of calibrating the sensor by moving sensing fluid into the sensing area, such as by using a pump. The method may also include the step of moving sensing fluid out of the sensing area as sensing fluid is moved into the sensing area. The sensing fluid may have a glucose concentration of between about 0 mg/dl and about 400 mg/dl. [0020] In embodiments in which the step of moving sensing fluid includes the steps of moving sensing fluid from a sensing fluid reservoir, the sensing fluid reservoir, sensing area, tissue piercing elements and at least part of the sensor may be supported by a first part of a housing, and the method further includes the step of attaching the first part of the housing to a second part of the housing prior to the inserting step, with the second part of the housing having an electrical connection to the at least part of the sensor in the first part of the housing. The method may also include the step of separating the second part of the housing from the first part of the housing after the sensing step. [0021] In some embodiments, the method includes the step of attaching the tissue piercing elements to the individual with adhesive. In other embodiments, the method includes the step of permitting glucose to diffuse from interstitial fluid of the individual through the distal openings into the interior space.
[0022] Another embodiment of the invention includes a glucose monitor comprising a plurality of tissue piercing elements, each tissue piercing element comprising a distal opening, a proximal opening and an interior space extending between the distal and proximal openings; a sensing area in continuous_fluid communication with the proximal openings of the tissue piercing elements; sensing fluid extending from the sensing area into substantially the entire interior space of the tissue piercing elements; and a glucose sensor adapted to continuously detect a concentration of glucose in the sensing fluid within the sensing area further adapted to be self-calibrating. [0023] Other embodiments of the invention will be apparent from the specification and drawings.
INCORPORATION BY REFERENCE
[0024] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0026] Figure 1 is a cross-sectional schematic view of a glucose monitoring device according to one embodiment of the invention in place on a user's skin.
[0027] Figure 2 shows an exploded view of a glucose monitoring device according to another embodiment of the invention.
[0028] Figures 3(a) and (b) are a schematic representative drawing of a three electrode system for use with the glucose sensor of one embodiment of this invention.
[0029] Figures 4(a) and (b) are a schematic representative drawing of a two electrode system for use with the glucose sensor of one embodiment of this invention. [0030] Figure 5 is a cross-sectional schematic view of a portion of a glucose monitoring device according to yet another embodiment of the invention.
[0031] Figure 6 shows a remote receiver for use with a glucose monitoring system according to yet another embodiment of the invention.
[0032] Figure 7 shows a glucose sensor in place on a user's skin and a remote monitor for use with the sensor.
DETAILED DESCRIPTION OF THE INVENTION
[0033] The present invention provides a significant advance in biosensor and glucose monitoring technology, portable, virtually non-invasive, self-calibrating, integrated and non-implanted sensors which continuously indicate the user's blood glucose concentration, enabling swift corrective action to be taken by the patient. The sensor and monitor of this invention may be used to measure other analytes as well, such as electrolytes like sodium or potassium ions. As will be appreciated by persons of skill in the art, the glucose sensor can be any suitable sensor including, for example, an electrochemical sensor an optical sensor.
[0034] Figure 1 shows a schematic cross-section of one embodiment of the invention in use. The glucose monitor 100 has an array of unique hollow microneedles 102 or other tissue piercing elements extending through the stratum corneum 104 of a user into the interstitial fluid 106 beneath the stratum corneum. Suitable microneedle arrays include those described in Stoeber et al. US Patent 6,406,638; US Patent Appl. Publ. No. 2005/0171480; and US Patent Appl. Publ. No. 2006/0025717. The needles in array 102 axe hollow and have open distal ends, and their interiors communicate with a sensing area 110 within a sensor channel 108. Sensing area 110 is therefore in fluid communication with interstitial fluid 106 through microneedle array 102. In this embodiment, sensing area 110 and the microneedles 102 are pre-filled with sensing fluid prior to the first use of the device. Thus, when the device is applied to the user's skin and the microneedles pierce the stratum corneum of the skin, there is substantially no net fluid transfer from the interstitial fluid into the microneedles. Rather, glucose diffuses from the interstitial fluid into the sensing fluid within the needles, as described below. [0035] Disposed above and in fluid communication with sensor channel 108 is a glucose sensor 112. In some embodiments, glucose sensor is an electrochemical glucose sensor that generates an electrical signal (current, voltage or charge) whose value depends on the concentration of glucose in the fluid within sensing area 110. Details of the operation of glucose sensor 112 are discussed in more detail below.
[0036] Sensor electronics element 114 receives the voltage signal from sensor 112. In some embodiments, sensor electronics element 114 uses the sensed signal to compute a glucose concentration and display it. In other embodiments, sensor electronics element 114 transmits the sensed signal, or information derived from the sensed signal, to a remote device, such as through wireless communication. Glucose monitor 100 is held in place on the skin 104 by one or more adhesive pads 116.
[0037] Glucose monitor 100 has a novel built-in sensor calibration system. A reservoir 118 containing a sensing fluid having, e.g., a glucose concentration between about 0 and about 400 mg/dl. In some embodiments, the glucose concentration in the sensing fluid is selected to be below the glucose sensing range of the sensor. The sensing fluid may also contain buffers, preservatives or other components in addition to the glucose. Upon actuation of a pump manually or automatically, plunger or other actuator 120, sensing fluid is forced from reservoir 118 through a check valve 122 (such as a flap valve) into sensing channel 108. Any sensing fluid within channel 108 is forced through a second check valve 124 (e.g., a flap valve) into a waste reservoir 126. Check valves or similar gating systems are used to prevent contamination. Because the fresh sensing fluid has a known glucose concentration, sensor 112 can be calibrated at this value to set a base line. After calibration, the sensing fluid in channel 108 remains stationary, and glucose from the interstitial fluid 106 diffuses through microneedles 102 into the sensing area 110: Changes in the glucose concentration from over time reflect differences between the calibration glucose concentration of the sensing fluid in the reservoir 118 and the glucose concentration of the interstitial fluid which can be correlated with the actual blood glucose concentration of the user using proprietary algorithms. Because of possible degradation of the sensor or loss of sensor sensitivity over time, the device may be periodically recalibrated by operating actuator 120 manually or automatically to send fresh sensing fluid from reservoir 118 into sensing area 110. [0038] In some embodiments, microneedle array 102, reservoirs 118 and 126, channel 108, sensor 112 and adhesive pads 116 are contained within a support structure (such as a housing 128) separate from electronics element 114 and actuator 120, which are supported within their own housing 130. This arrangement permits the sensor, sensing fluid and microneedles to be discarded after a period of use (e.g., when reservoir 118 is depleted) while enabling the electronics and actuator to be reused. A flexible covering (made, e.g., of polyester or other plastic-like material) may surround and support the disposable components. In particular, the interface between actuator 120 and reservoir 118 must permit actuator 120 to move sensing fluid out of reservoir 118, such as by deforming a wall of the reservoir. In these embodiments, housings 128 and 130 may have a mechanical connection, such as a snap or interference fit. [0039] Figure 2 shows an exploded view of another embodiment of the invention. This figure shows a removable seal 203 covering the sharp distal ends of microneedles 202 and attached, e.g., by adhesive. Seal 203 maintains the sensing fluid within the microneedles and sensing area prior to use and is removed prior to placing the glucose monitor 200 on the skin using adhesive pressure seal 216. In this embodiment, microneedles 202, sensing fluid and waste reservoirs 218 and 226, sensing microchannel 208 and electrochemical glucose sensor 212 are contained within and/or supported by a housing 228 which forms the disposable portion of the device. A second housing 230 supports an electronics board 214 (containing, e.g., processing circuitry, a power source, transmission circuitry, etc.) and an actuator 220 that can be used to move sensing fluid out of reservoir 218, through microchannel 208 into waste reservoir 226. Electrical contacts 215 extend from electronics board 214 to make contact with corresponding electrodes in glucose sensor 212 when the device is assembled. [0040] The following is a description of glucose sensors that may be used with the glucose monitors of this invention. In 1962 Clark and Lyons proposed the first enzyme electrode (that was implemented later by Updike and Hicks) to determine glucose concentration in a sample by combining the specificity of a biological system with the simplicity and sensitivity of an electrochemical transducer. The most common strategies for glucose detection are based on using either glucose oxidase or glucose dehydrogenase enzyme. [0041] Electrochemical sensors for glucose, based on the specific glucose oxidizing enzyme glucose oxidase, have generated considerable interest. Several commercial devices based on this principle have been developed and are widely used currently for monitoring of glucose, e.g., self testing by patients at home, as well as testing in physician offices and hospitals. The earliest amperometric glucose biosensors were based on glucose oxidase (GOX) which generates hydrogen peroxide in the presence of oxygen and glucose according to the following reaction scheme: Glucose + GOX-FAD (ox) -> Gluconolactone + GOX-FADH2 (red)
GOX-FADH2 (red) + O2 -> GOX-FAD (ox) + H2O2
[0042] Electrochemical biosensors are used for glucose detection because of their high sensitivity, selectivity and low cost. In principal, amperometric detection is based on measuring either the oxidation or reduction of an electroactive compound at a working electrode (sensor). A constant potential is applied to that working electrode with respect to another electrode used as the reference electrode. The glucose oxidase enzyme is first reduced in the process but is reoxidized again to its active form by the presence of any oxygen resulting in the formation of hydrogen peroxide. Glucose sensors generally have been designed by monitoring either the hydrogen peroxide formation or the oxygen consumption. The hydrogen peroxide produced is easily detected at a potential of +0.6 V relative to a reference electrode such as an Ag/AgCl electrode. However, sensors based on hydrogen peroxide detection are subject to electrochemical interference by the presence of other oxidizable species in clinical samples such as blood or serum. On the other hand, biosensors based on oxygen consumption are affected by the variation of oxygen concentration in ambient air. In order to overcome these drawbacks, different strategies have been developed and adopted. [0043] Selectively permeable membranes or polymer films have been used to suppress or minimize interference from endogenous electroactive species in biological samples. Another strategy to solve these problems is to replace oxygen with electrochemical mediators to reoxidize the enzyme. Mediators are electrochemically active compounds that can reoxidize the enzyme (glucose oxidase) and then be reoxidized at the working electrode as shown below: GOX-FADH2 (red) + Mediator (ox) -> GOX-FAD (ox) + Mediator (red)
[0044] Organic conducting salts, ferrocene and ferrocene derivatives, ferricyanide, quinones, and viologens are considered good examples of such mediators. Such electrochemical mediators act as redox couples to shuttle electrons between the enzyme and electrode surface. Because mediators can be detected at lower oxidation potentials than that used for the detection of hydrogen peroxide the interference from electroactive species (e.g., ascorbic and uric acids present) in clinical samples such as blood or serum is greatly reduced. For example ferrocene derivatives have oxidation potentials in the +0.1 to 0.4 V range. Conductive organic salts such as tetrathiafulvalene- tetracyanoquinodimethane (TTF-TCNQ) can operate as low as 0.0 Volts relative to a Ag/AgCl reference electrode. Nankai et al, WO 86/07632, published Dec. 31, 1986, discloses an amperometric biosensor system in which a fluid containing glucose is contacted with glucose oxidase and potassium ferricyanide. The glucose is oxidized and the ferricyanide is reduced to ferrocyanide. This reaction is catalyzed by glucose oxidase. After two minutes, an electrical potential is applied, and a current caused by the re-oxidation of the ferrocyanide to femcyanide is obtained. The current value, obtained a few seconds after the potential is applied, correlates to the concentration of glucose in the fluid. [0045] There are multiple glucose sensors that may be used with this invention. In a three electrode system, shown in Figure 3(a), a working electrode 302 is referenced against a reference electrode 304 (such as Ag/AgCl) and a counter electrode 306 (such as Pt) provides a means for current flow. The three electrodes are mounted on a substrate 308, then covered with a reagent 310, as shown in Figure 3(b). [0046] Figure 4 shows a two electrode system, wherein the working and counter electrodes 402 and 404 are made of different electrically conducting materials. Like the embodiment of Figure 3, the electrodes 402 and 404 are mounted on a flexible substrate 408 as shown in Figure 4(a) and covered with a reagent 410, as shown in Figure 4(b). In an alternative two electrode system, the working and counter electrodes are made of the same electrically conducting materials, where the reagent exposed surface area of the counter electrode is slightly larger than that of the working electrode or where both the working and counter electrodes are substantially of equal dimensions. [0047] In amperometric and coulometric biosensors, immobilization of the enzymes is also very important.
Conventional methods of enzyme immobilization include covalent binding, physical adsorption or cross-linking to a suitable matrix may be used.
[0048] In some embodiments, the reagent is contained in a reagent well in the biosensor. The reagent includes a redox mediator, an enzyme, and a buffer, and covers substantially equal surface areas of portions of the working and counter electrodes. When a sample containing the analyte to be measured, in this case glucose, comes into contact with the glucose biosensor the analyte is oxidized, and simultaneously the mediator is reduced. After the reaction is complete, an electrical potential difference is applied between the electrodes. In general the amount of oxidized form of the redox mediator at the counter electrode and the applied potential difference must be sufficient to cause diffusion limited electrooxidation of the reduced form of the redox mediator at the surface of the working electrode. After a short time delay, the current produced by the electrooxidation of the reduced form of the redox mediator is measured and correlated to the amount of the analyte concentration in the sample. In some cases, the analyte sought to be measured may be reduced and the redox mediator may be oxidized.
[0049] In the present invention, these requirements are satisfied by employing a readily reversible redox mediator and using a reagent with the oxidized form of the redox mediator in an amount sufficient to insure that the diffusion current produced is limited by the oxidation of the reduced form of the redox mediator at the working electrode surface. For current produced during electrooxidation to be limited by the oxidation of the reduced form of the redox mediator at the working electrode surface, the amount of the oxidized form of the redox mediator at the surface of the counter electrode must always exceed the amount of the reduced form of the redox mediator at the surface of the working electrode. Importantly, when the reagent includes an excess of the oxidized form of the redox mediator, as described below, the working and counter electrodes may be substantially the same size or unequal size as well as made of the same or different electrically conducting material or different conducting materials. From a cost perspective the ability to utilize electrodes that are fabricated from substantially the same material represents an important advantage for inexpensive biosensors.
[0050] As explained above, the redox mediator must be readily reversible, and the oxidized form of the redox mediator must be of sufficient type to receive at least one electron from the reaction involving enzyme, analyte, and oxidized form of the redox mediator. For example, when glucose is the analyte to be measured and glucose oxidase is the enzyme, ferricyanide or quinone may be the oxidized form of the redox mediator. Other examples of enzymes and redox mediators (oxidized form) that may be used in measuring particular analytes by the present invention are ferrocene and or ferrocene derivative, ferricyanide, and viologens. Buffers may be used to provide a preferred pH range from about 4 to 8. The most preferred pH range is from about 6 to 7. The most preferred buffer is phosphate (e.g., potassium phosphate) from about 0. IM to 0.5M and preferably about 0.4M. (These concentration ranges refer to the reagent composition before it is dried onto the electrode surfaces.) More details regarding glucose sensor chemistry and operation may be found in: Clark LC. and Lyons C. "Electrode Systems for Continuous Monitoring in Cardiovascular Surgery," Ann NY Acad Sci, 102:29, 1962; Updike SJ, and Hicks GP. "The Enzyme Electrode," Nature, 214:986, 1967; Cass, A.E. G., G. Davis. G.D. Francis, et. al. 1984. Ferrocene -mediated enzyme electrode for amperometric determination of glucose. Anal.Chem. 56:667-671; and Boutelle, M.G..C. Stanford. M. Fillenz. etal. 1986. An amperometric enzyme electrode for monitoring brain glucose in the freely moving rat. Neurosci lett. 72:283-288.
[0051] Another embodiment of the disposable portion of the glucose monitor invention is shown in Figure 5 with a microneedle array 502 and a glucose sensor 512 in fluid communication with a sensing area in channel 508. In this embodiment, actuator 520 is on the side of sensing fluid reservoir 518, and the waste reservoir 526 is expandable. Operation of actuator 520 sends sensing fluid from reservoir 518 through one way flap valve 522 into the sensing area in channel 508 and forces sensing fluid within channel 508 through flap valve 524 into the expandable waste reservoir 526.
[0052] In the embodiment of Figure 5 (and potentially other embodiments), the starting amount of sensing fluid in the calibration reservoir 518 is about 1.0 ml or less, and operation of the sensing fluid actuator 520 sends a few microliters (e.g., 10 μL) of sensing fluid into channel 508. Recalibrating the device three times a day for seven days will use less than 250 μL of sensing fluid.
[0053] Figures 6 and 7 show a remote receiver for use with a glucose monitoring system. The wireless receiver can be configured to be worn by a patient on a belt, or carried in a pocket or purse. In this embodiment, glucose sensor information is transmitted by the glucose sensor 602 applied to the user's skin to receiver 600 using, e.g., wireless communication such as radio frequency (RF) or Bluetooth wireless. The receiver may maintain a continuous link with the sensor, or it may periodically receive information from the sensor. The sensor and its receiver may be synchronized using RFID technology or other unique identifiers. Receiver 600 may be provided with a display 604 and user controls 606. The display may show, e.g., glucose values, directional glucose trend arrows and rates of change of glucose concentration. The receiver can also be configured with a speaker adapted to deliver an audible alarm, such as high and low glucose alarms. Additionally, the receiver can include a memory device, such as a chip, that is capable of storing glucose data for analysis by the user or by a health care provider. [0054] In some embodiments, the source reservoir for the calibration and sensing fluid may be in a blister pack which maintains its integrity until punctured or broken. The actuator may be a small syringe or pump. Use of the actuator for recalibration of the sensor may be performed manually by the user or may be performed automatically by the device if programmed accordingly. There may also be a spring or other loading mechanism within the reusable housing that can be activated to push the disposable portion — and specifically the microneedles — downward into the user's skin.
[0055] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

CLAIMS WHAT IS CLAIMED IS:
1. A glucose monitor comprising a plurality of tissue piercing elements, each tissue piercing element comprising a distal opening, a proximal opening and an interior space extending between the distal and proximal openings; a sensing area in fluid communication with the proximal openings of the tissue piercing elements; sensing fluid extending from the sensing area into substantially the entire interior space of the tissue piercing elements; and a glucose sensor adapted to detect a concentration of glucose in the sensing fluid within the sensing area.
2. The glucose monitor of claim 1 further comprising a removable cover extending over the distal openings of the tissue piercing elements.
3. The glucose monitor of claim 1 further comprising a display adapted to display a glucose concentration sensed by the sensor.
4. The glucose monitor of claim 3 wherein the display is disposed in a housing separate from the sensor, the glucose monitor further comprising a communicator adapted to wirelessly communicate sensor information from the sensor to the display.
5. The glucose monitor of claim 1 further comprising a sensing fluid reservoir and a pump adapted to move sensing fluid out of the sensing fluid reservoir into the sensing area.
6. The glucose monitor of claim 5 wherein the pump comprises a manual actuator.
7. The glucose monitor of claim S further comprising a waste reservoir adapted to receive sensing fluid from the sensing area.
8. The glucose monitor of claim 7 further comprising a housing comprising a first part and a second part, the first part of the housing being adapted to support the tissue piercing elements, the sensing fluid reservoir, the sensing area, and at least part of the sensor, the second part of the housing comprising an electrical connection to the at least part of the sensor in the first part of the housing, the housing further comprising a connector adapted to connect and disconnect the first part of the housing from the second part of the housing.
9. The glucose monitor of claim 8 wherein the first part of the housing is further adapted to support the pump.
10. The glucose monitor of claim 8 wherein the first part of the housing is further adapted to support the waste reservoir.
11. The glucose monitor of claim 8 further comprising a communicator supported by the second part of the housing and adapted to communicate sensor information to a display.
12. The glucose monitor of claim 5 wherein the sensing fluid in the sensing fluid reservoir has a glucose concentration of between about 0 mg/dl and about 400 mg/dl.
13. The glucose monitor of claim 1 further comprising an adhesive element adjacent the tissue piercing elements and adapted to attach to a user's skin.
14. The glucose monitor of claim 1 wherein the glucose sensor, tissue piercing elements and sensing area are further adapted to detect a concentration of glucose in the sensing fluid within the sensing area without extracting interstitial fluid through the distal openings into the interior space.
15. A method of in vivo monitoring of an individual ' s interstitial fluid glucose concentration comprising: inserting distal ends of a plurality of tissue piercing elements through a stratum corneum area of the individual's skin, the tissue piercing elements each comprising a distal opening, a proximal opening, an inferior space extending between the distal and proximal openings, and a sensing fluid filling substantially the entire interior space; and sensing a glucose concentration of the sensing fluid.
16. The method of claim 15 further comprising removing a cover from the distal openings of the tissue piercing elements prior to the inserting step.
17. The method of claim 15 further comprising displaying glucose concentration information remote from the stratum corneum area of the individual's skin.
18. The method of claim 17 further comprising wirelessly communicating glucose concentration information to a display.
19. The method of claim 15 wherein the sensing step is performed by a sensor in fluid communication with a sensing area and the interior spaces of the tissue piercing elements, the method further comprising calibrating the sensor by moving sensing fluid into the sensing area.
20. The method of claim 19 further comprising moving sensing fluid out of the sensing area as sensing fluid is moved into the sensing area.
21. The method of claim 19 wherein the step of moving sensing fluid comprises operating a pump.
22. The method of claim 19 wherein the step of moving sensing fluid comprises moving sensing fluid having a glucose concentration of between about 0 mg/dl and about 400 mg/dl.
23. The method of claim 19 wherein the step of moving sensing fluid comprises moving sensing fluid from a sensing fluid reservoir, the sensing fluid reservoir, sensing area, tissue piercing elements and at least part of the sensor being supported by a first part of a housing, the method further comprising attaching the first part of the housing to a second part of the housing prior to the inserting step, the second part of the housing comprising an electrical connection to the at least part of the sensor in the first part of the housing.
24. The method of claim 23 further comprising separating the second part of the housing from the first part of the housing after the sensing step.
25. The method of claim 15 further comprising attaching the tissue piercing elements to the individual with adhesive.
26. The method of claim 15 further comprising permitting glucose to diffuse from interstitial fluid of the individual into the sensing area without extracting interstitial fluid through the distal openings into the interior space.
27. A glucose monitor comprising a plurality of tissue piercing elements, each tissue piercing element comprising a distal opening, a proximal opening and an interior space extending between the distal and proximal openings; a sensing area in continuous_fluid communication with the proximal openings of the tissue piercing elements; sensing fluid extending from the sensing area into substantially the entire interior space of the tissue piercing elements; and a glucose sensor adapted to continuously detect a concentration of glucose in the sensing fluid within the sensing area and further adapted to be self-calibrating.
PCT/US2006/011382 2005-03-29 2006-03-28 Devices, systems, methods and tools for continuous glucose monitoring WO2006105146A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06748841A EP1869414A4 (en) 2005-03-29 2006-03-28 Devices, systems, methods and tools for continuous glucose monitoring
CA002602259A CA2602259A1 (en) 2005-03-29 2006-03-28 Devices, systems, methods and tools for continuous glucose monitoring

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66677505P 2005-03-29 2005-03-29
US60/666,775 2005-03-29
US74308005P 2005-12-27 2005-12-27
US60/743,080 2005-12-27

Publications (2)

Publication Number Publication Date
WO2006105146A2 true WO2006105146A2 (en) 2006-10-05
WO2006105146A3 WO2006105146A3 (en) 2007-11-15

Family

ID=37054048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011382 WO2006105146A2 (en) 2005-03-29 2006-03-28 Devices, systems, methods and tools for continuous glucose monitoring

Country Status (4)

Country Link
US (2) US8280476B2 (en)
EP (1) EP1869414A4 (en)
CA (1) CA2602259A1 (en)
WO (1) WO2006105146A2 (en)

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1929941A1 (en) * 2006-12-07 2008-06-11 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Portable device for the measurement and control of analytes in biological fluids
WO2008157255A1 (en) * 2007-06-14 2008-12-24 Arkal Medical, Inc. On-demand analyte monitor and method of use
WO2009049243A2 (en) * 2007-10-12 2009-04-16 Arkal Medical, Inc. Microneedle array with diverse needle configurations
ES2353181A1 (en) * 2010-09-01 2011-02-28 Francisco Javie Garcia Saban Device for continuous measuring of an analyte
US7949382B2 (en) 2005-03-29 2011-05-24 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US9042953B2 (en) 1998-04-30 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9041730B2 (en) 2010-02-12 2015-05-26 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US9044199B2 (en) 2004-07-13 2015-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US9050413B2 (en) 2004-02-26 2015-06-09 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9055901B2 (en) 2004-07-13 2015-06-16 Dexcom, Inc. Transcutaneous analyte sensor
US9066697B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9078607B2 (en) 2005-11-01 2015-07-14 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9078608B2 (en) 2005-03-10 2015-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9610034B2 (en) 2001-01-02 2017-04-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9649069B2 (en) 2003-08-22 2017-05-16 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9668677B2 (en) 2004-07-13 2017-06-06 Dexcom, Inc. Analyte sensor
US9668682B2 (en) 2007-09-13 2017-06-06 Dexcom, Inc. Transcutaneous analyte sensor
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US9717449B2 (en) 2007-10-25 2017-08-01 Dexcom, Inc. Systems and methods for processing sensor data
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9741139B2 (en) 2007-06-08 2017-08-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US9750441B2 (en) 2003-12-09 2017-09-05 Dexcom, Inc. Signal processing for continuous analyte sensor
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9804114B2 (en) 2001-07-27 2017-10-31 Dexcom, Inc. Sensor head for use with implantable devices
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US9861310B2 (en) 2014-10-17 2018-01-09 Fitscript Llc Algorithms for diabetes exercise therapy
US9895089B2 (en) 2003-08-01 2018-02-20 Dexcom, Inc. System and methods for processing analyte sensor data
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10034628B2 (en) 2003-06-11 2018-07-31 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US10136844B2 (en) 2006-10-04 2018-11-27 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10188333B2 (en) 2003-12-05 2019-01-29 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US10201301B2 (en) 2005-11-01 2019-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
EP3485814A1 (en) * 2017-11-20 2019-05-22 Microjet Technology Co., Ltd Blood glucose detection device
US10349873B2 (en) 2006-10-04 2019-07-16 Dexcom, Inc. Analyte sensor
US10478108B2 (en) 1998-04-30 2019-11-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10537678B2 (en) 2009-03-27 2020-01-21 Dexcom, Inc. Methods and systems for promoting glucose management
US10602968B2 (en) 2008-03-25 2020-03-31 Dexcom, Inc. Analyte sensor
US10653835B2 (en) 2007-10-09 2020-05-19 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US10667733B2 (en) 2009-09-30 2020-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US10966609B2 (en) 2004-02-26 2021-04-06 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US11102306B2 (en) 2008-02-21 2021-08-24 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11382539B2 (en) 2006-10-04 2022-07-12 Dexcom, Inc. Analyte sensor
US11432772B2 (en) 2006-08-02 2022-09-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11559260B2 (en) 2003-08-22 2023-01-24 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11564602B2 (en) 2003-11-19 2023-01-31 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155496B2 (en) 1997-03-04 2015-10-13 Dexcom, Inc. Low oxygen in vivo analyte sensor
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7415299B2 (en) * 2003-04-18 2008-08-19 The Regents Of The University Of California Monitoring method and/or apparatus
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US20060281187A1 (en) 2005-06-13 2006-12-14 Rosedale Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control
KR100692783B1 (en) * 2005-07-19 2007-03-12 케이엠에이치 주식회사 Patch for extracting glucose
CA2623589C (en) 2005-09-30 2014-07-22 Intuity Medical, Inc. Catalysts for body fluid sample extraction
US7885698B2 (en) * 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20090131778A1 (en) * 2006-03-28 2009-05-21 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US20080154107A1 (en) * 2006-12-20 2008-06-26 Jina Arvind N Device, systems, methods and tools for continuous glucose monitoring
US20070276211A1 (en) * 2006-05-26 2007-11-29 Jose Mir Compact minimally invasive biomedical monitor
US20100100005A1 (en) * 2006-07-11 2010-04-22 Infotonics Technology Center, Inc. Minimally invasive allergy testing system with coated allergens
US20080058726A1 (en) * 2006-08-30 2008-03-06 Arvind Jina Methods and Apparatus Incorporating a Surface Penetration Device
US20080234562A1 (en) * 2007-03-19 2008-09-25 Jina Arvind N Continuous analyte monitor with multi-point self-calibration
US8160900B2 (en) * 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
US7661290B2 (en) * 2007-07-20 2010-02-16 Honeywell International Inc. Gas sensor test and calibration system
US8328720B2 (en) * 2007-08-10 2012-12-11 Infotonics Technology Center, Inc. MEMS interstitial prothrombin time test
WO2009029572A1 (en) * 2007-08-24 2009-03-05 Deka Products Limited Partnership Microneedle systems and apparatus
WO2009124095A1 (en) * 2008-03-31 2009-10-08 Abbott Diabetes Care Inc. Shallow implantable analyte sensor with rapid physiological response
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
WO2009145920A1 (en) 2008-05-30 2009-12-03 Intuity Medical, Inc. Body fluid sampling device -- sampling site interface
JP5642066B2 (en) 2008-06-06 2014-12-17 インテュイティ メディカル インコーポレイテッド Method and apparatus for performing an assay to determine the presence or concentration of an analyte contained in a sample of body fluid
US8700114B2 (en) * 2008-07-31 2014-04-15 Medtronic Minmed, Inc. Analyte sensor apparatuses comprising multiple implantable sensor elements and methods for making and using them
US9445755B2 (en) * 2008-11-14 2016-09-20 Pepex Biomedical, Llc Electrochemical sensor module
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
EP2506768B1 (en) 2009-11-30 2016-07-06 Intuity Medical, Inc. Calibration material delivery devices and methods
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US20120157801A1 (en) * 2010-11-18 2012-06-21 Abbott Diabetes Care Inc. Adaptor for On-Body Analyte Monitoring System
US10244981B2 (en) * 2011-03-30 2019-04-02 SensiVida Medical Technologies, Inc. Skin test image analysis apparatuses and methods thereof
EP4339613A2 (en) 2011-08-03 2024-03-20 Intuity Medical, Inc. Body fluid sampling arrangement
WO2013058879A2 (en) 2011-09-02 2013-04-25 The Regents Of The University Of California Microneedle arrays for biosensing and drug delivery
US9375172B2 (en) 2011-11-07 2016-06-28 Corning Incorporated Apparatus for substance detection
US9042596B2 (en) 2012-06-14 2015-05-26 Medibotics Llc Willpower watch (TM)—a wearable food consumption monitor
US10314492B2 (en) 2013-05-23 2019-06-11 Medibotics Llc Wearable spectroscopic sensor to measure food consumption based on interaction between light and the human body
US9536449B2 (en) 2013-05-23 2017-01-03 Medibotics Llc Smart watch and food utensil for monitoring food consumption
US9254099B2 (en) 2013-05-23 2016-02-09 Medibotics Llc Smart watch and food-imaging member for monitoring food consumption
US9442100B2 (en) 2013-12-18 2016-09-13 Medibotics Llc Caloric intake measuring system using spectroscopic and 3D imaging analysis
CN103908266B (en) * 2013-01-09 2015-12-02 北京怡成生物电子技术股份有限公司 Miniature bodily fluid sampling device
CN105228522B (en) 2013-03-14 2018-06-26 萨诺智能公司 For the microsensor on the human body of biological monitoring
CA2904031A1 (en) 2013-03-14 2014-10-02 Profusa, Inc. Method and device for correcting optical signals
US10820860B2 (en) 2013-03-14 2020-11-03 One Drop Biosensor Technologies, Llc On-body microsensor for biomonitoring
US9486171B2 (en) 2013-03-15 2016-11-08 Tandem Diabetes Care, Inc. Predictive calibration
US9529385B2 (en) 2013-05-23 2016-12-27 Medibotics Llc Smart watch and human-to-computer interface for monitoring food consumption
EP3777656A1 (en) 2013-06-06 2021-02-17 Profusa, Inc. Apparatus for detecting optical signals from implanted sensors
US20150173674A1 (en) * 2013-12-20 2015-06-25 Diabetes Sentry Products Inc. Detecting and communicating health conditions
US9770207B2 (en) 2013-12-23 2017-09-26 Verily Life Sciences Llc Sensor electrodes in a bio-compatible device
CA2933166C (en) 2013-12-31 2020-10-27 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US20150257687A1 (en) 2014-03-13 2015-09-17 Sano Intelligence, Inc. System for monitoring body chemistry
US10595754B2 (en) 2014-03-13 2020-03-24 Sano Intelligence, Inc. System for monitoring body chemistry
US9933387B1 (en) 2014-09-07 2018-04-03 Biolinq, Inc. Miniaturized sub-nanoampere sensitivity low-noise potentiostat system
US10987039B2 (en) 2014-12-03 2021-04-27 Stmicroelectronics S.R.L. Microneedle array device and method of making
US10251605B2 (en) 2015-02-16 2019-04-09 Verily Life Sciences Llc Bandage type of continuous glucose monitoring system
US10201295B2 (en) 2015-03-13 2019-02-12 Verily Life Sciences Llc User interactions for a bandage type monitoring device
US10046114B1 (en) 2015-05-22 2018-08-14 Verily Life Sciences Llc Control of a peripheral device with a bandage-type analyte sensor
US10292630B2 (en) 2015-06-01 2019-05-21 Verily Life Sciences Llc Optical sensor for bandage type monitoring device
WO2016205558A1 (en) 2015-06-18 2016-12-22 Ultradian Diagnostics Llc Methods and devices for determining metabolic states
US10765353B2 (en) 2015-07-02 2020-09-08 Verily Life Sciences Llc Calibration methods for a bandage-type analyte sensor
US10105100B2 (en) 2015-07-28 2018-10-23 Verily Life Sciences Llc Display on a bandage-type monitoring device
EP3138488B1 (en) 2015-09-02 2019-06-05 Roche Diabetes Care GmbH Sensor module and kit for determining an analyte concentration
SI3138489T1 (en) 2015-09-02 2020-10-30 F. Hoffmann-La Roche Ag Kit for determining an analyte concentration
US10213144B2 (en) 2016-01-25 2019-02-26 International Business Machines Corporation Nanopatterned biosensor electrode for enhanced sensor signal and sensitivity
US10092207B1 (en) 2016-05-15 2018-10-09 Biolinq, Inc. Tissue-penetrating electrochemical sensor featuring a co-electrodeposited thin film comprised of polymer and bio-recognition element
US10376193B2 (en) 2016-07-25 2019-08-13 International Business Machines Corporation Embedded sacrificial layer to enhance biosensor stability and lifetime for nanopatterned electrodes
WO2018132578A1 (en) 2017-01-11 2018-07-19 Tandem Diabetes Care, Inc. Electromagnetic signal-based infusion pump control
IT201700002389A1 (en) * 2017-01-12 2017-04-12 Matteo Giuseppe Cimmino MONITORING DEVICE FOR LEVELS OF GLUCOSE IN THE BODY.
US10161898B2 (en) 2017-01-30 2018-12-25 International Business Machines Corporation Nanopatterned biosensor electrode for enhanced sensor signal and sensitivity
US10548530B2 (en) 2017-03-01 2020-02-04 International Business Machines Corporation Biosensor calibration structure containing different sensing surface area
US11562907B2 (en) 2018-11-29 2023-01-24 International Business Machines Corporation Nanostructure featuring nano-topography with optimized electrical and biochemical properties
WO2020171838A1 (en) 2019-02-19 2020-08-27 Tandem Diabetes Care, Inc. System and method of pairing an infusion pump with a remote control device
US11305057B2 (en) 2019-03-26 2022-04-19 Tandem Diabetes Care, Inc. Method and system of operating an infusion pump with a remote control device
DK4048152T3 (en) 2020-07-29 2024-03-11 Biolinq Incorporated SYSTEM FOR CONTINUOUS ANALYTE MONITORING WITH MICRON NEEDLE ARRANGEMENT
USD988882S1 (en) 2021-04-21 2023-06-13 Informed Data Systems Inc. Sensor assembly
CN116113454A (en) 2021-05-08 2023-05-12 比奥林股份有限公司 Continuous analyte monitoring device fault detection based on microneedle arrays

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143746A1 (en) 2002-01-31 2003-07-31 Sage Burton H. Self-calibrating body anayte monitoring system
US6652478B1 (en) 1999-06-09 2003-11-25 The Procter & Gamble Company Intracutaneous edged microneedle apparatus
US20040096959A1 (en) 2000-12-19 2004-05-20 Matthias Stiene Analyte measurement
US20050027179A1 (en) 1998-03-13 2005-02-03 Cygnus, Inc. Biosensor and methods of use thereof

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US4018938A (en) * 1975-06-30 1977-04-19 International Business Machines Corporation Fabrication of high aspect ratio masks
US4071020A (en) 1976-06-03 1978-01-31 Xienta, Inc. Apparatus and methods for performing in-vivo measurements of enzyme activity
US4165395A (en) * 1977-06-30 1979-08-21 International Business Machines Corporation Process for forming a high aspect ratio structure by successive exposures with electron beam and actinic radiation
JPS5590931A (en) * 1978-12-29 1980-07-10 Canon Inc Production of micro structure element array
US4320758A (en) 1979-05-07 1982-03-23 Alza Corporation Osmotically driven fluid dispenser
US4846950A (en) * 1983-09-08 1989-07-11 Montefiore Hospital Assn Of Western Pa Cyclic controlled electrolysis apparatus
DE3687646T3 (en) 1985-06-21 2001-05-31 Matsushita Electric Ind Co Ltd BIOSENSOR AND THEIR PRODUCTION.
US4821733A (en) 1987-08-18 1989-04-18 Dermal Systems International Transdermal detection system
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
US5208147A (en) * 1988-07-21 1993-05-04 Radiometer A/S Means for measuring a characteristic in a sample fluid
US5899856A (en) 1988-09-08 1999-05-04 Sudormed, Inc. Dermal patch detecting long-term alcohol consumption and method of use
US5817012A (en) 1988-09-08 1998-10-06 Sudormed, Inc. Method of determining an analyte
US5438984A (en) 1988-09-08 1995-08-08 Sudor Partners Apparatus and method for the collection of analytes on a dermal patch
US5076273A (en) 1988-09-08 1991-12-31 Sudor Partners Method and apparatus for determination of chemical species in body fluid
US5096669A (en) 1988-09-15 1992-03-17 I-Stat Corporation Disposable sensing device for real time fluid analysis
US5112455A (en) 1990-07-20 1992-05-12 I Stat Corporation Method for analytically utilizing microfabricated sensors during wet-up
DE69130854T2 (en) * 1990-11-21 1999-08-05 Canon Kk Laser processing machine
US5312456A (en) * 1991-01-31 1994-05-17 Carnegie Mellon University Micromechanical barb and method for making the same
JP2961334B2 (en) 1991-05-28 1999-10-12 セイコーインスツルメンツ株式会社 Atomic force microscope cantilever manufacturing method with sharp metal needle
DE4222856C1 (en) * 1992-07-11 1993-05-27 Buerkert Gmbh
JP2541081B2 (en) * 1992-08-28 1996-10-09 日本電気株式会社 Biosensor and method of manufacturing and using biosensor
US5821399A (en) 1993-07-16 1998-10-13 I-Stat Corporation Automatic test parameters compensation of a real time fluid analysis sensing device
GB9320850D0 (en) 1993-10-09 1993-12-01 Terwee Thomas H M Monitoring the concentration of a substance or a group of substances in a body fluid of a human or an animal
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5447440A (en) 1993-10-28 1995-09-05 I-Stat Corporation Apparatus for assaying viscosity changes in fluid samples and method of conducting same
US20020169394A1 (en) 1993-11-15 2002-11-14 Eppstein Jonathan A. Integrated tissue poration, fluid harvesting and analysis device, and method therefor
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
DE4401400A1 (en) 1994-01-19 1995-07-20 Ernst Prof Dr Pfeiffer Method and arrangement for continuously monitoring the concentration of a metabolite
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US6093520A (en) * 1994-09-09 2000-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College High aspect ratio microstructures and methods for manufacturing microstructures
DE19525607A1 (en) * 1995-07-14 1997-01-16 Boehringer Ingelheim Kg Transcorneal drug delivery system
US5989409A (en) 1995-09-11 1999-11-23 Cygnus, Inc. Method for glucose sensing
US5735273A (en) 1995-09-12 1998-04-07 Cygnus, Inc. Chemical signal-impermeable mask
DE19602861C2 (en) 1996-01-28 1997-12-11 Meinhard Prof Dr Knoll Sampling system for analytes contained in carrier liquids and method for its production
DE19618597B4 (en) 1996-05-09 2005-07-21 Institut für Diabetestechnologie Gemeinnützige Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm Method for determining the concentration of tissue glucose
US6230051B1 (en) 1996-06-18 2001-05-08 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US6139718A (en) 1997-03-25 2000-10-31 Cygnus, Inc. Electrode with improved signal to noise ratio
US5747666A (en) 1997-03-26 1998-05-05 Willis; John P. Point-of-care analyzer module
CA2294610A1 (en) 1997-06-16 1998-12-23 George Moshe Katz Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods
US5928207A (en) 1997-06-30 1999-07-27 The Regents Of The University Of California Microneedle with isotropically etched tip, and method of fabricating such a device
US6223591B1 (en) 1997-11-28 2001-05-01 Nikon Corporation Probe needle arrangement and movement method for use in an atomic force microscope
ATE221400T1 (en) 1997-12-11 2002-08-15 Alza Corp DEVICE FOR INCREASE THE TRANSDERMAL FLOW OF ACTIVE INGREDIENTS
KR100557261B1 (en) 1997-12-11 2006-03-07 알자 코포레이션 Device for enhancing transdermal agent flux
US7066884B2 (en) 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US6190315B1 (en) 1998-01-08 2001-02-20 Sontra Medical, Inc. Sonophoretic enhanced transdermal transport
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
NL1008315C2 (en) 1998-02-16 1999-08-25 Stichting Fund Ond Material Microdialysis probe integrated with Si chip.
US6106751A (en) 1998-03-18 2000-08-22 The Regents Of The University Of California Method for fabricating needles via conformal deposition in two-piece molds
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
CA2332112C (en) 1998-05-13 2004-02-10 Cygnus, Inc. Monitoring of physiological analytes
CA2311487C (en) 1998-05-13 2004-02-10 Cygnus, Inc. Signal processing for measurement of physiological analytes
EP1086214B1 (en) 1998-06-10 2009-11-25 Georgia Tech Research Corporation Microneedle devices and methods of their manufacture
US7344499B1 (en) * 1998-06-10 2008-03-18 Georgia Tech Research Corporation Microneedle device for extraction and sensing of bodily fluids
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6602678B2 (en) * 1998-09-04 2003-08-05 Powderject Research Limited Non- or minimally invasive monitoring methods
DE69913153D1 (en) 1998-09-17 2004-01-08 Cygnus Therapeutic Systems DEVICE FOR COMPRESSING A GEL / SENSOR UNIT
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US6223471B1 (en) * 1998-12-31 2001-05-01 Jerry Keith Barber Sliding door with wheel repair kit
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2002542498A (en) 1999-04-22 2002-12-10 シグナス, インコーポレイテッド Methods and devices for removing interfering species
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6312612B1 (en) 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6835184B1 (en) 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
ATE310561T1 (en) 1999-12-10 2005-12-15 Alza Corp APPARATUS AND METHOD FOR IMPROVING MICRONEEDLE SKIN PIERCING
US6406638B1 (en) 2000-01-06 2002-06-18 The Regents Of The University Of California Method of forming vertical, hollow needles within a semiconductor substrate, and needles formed thereby
IL134997A0 (en) * 2000-03-09 2001-05-20 Yehoshua Yeshurun Health care system based on micro device
US6558361B1 (en) 2000-03-09 2003-05-06 Nanopass Ltd. Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems
US20030153620A1 (en) * 2000-05-12 2003-08-14 Meakin Timothy David Treating eczema and/or psoriasis
WO2001088534A2 (en) 2000-05-16 2001-11-22 Cygnus, Inc. Methods for improving performance and reliability of biosensors
US6565532B1 (en) 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
US6603987B2 (en) 2000-07-11 2003-08-05 Bayer Corporation Hollow microneedle patch
DE10038835B4 (en) 2000-08-04 2005-07-07 Roche Diagnostics Gmbh Microdialysis system
US6533949B1 (en) * 2000-08-28 2003-03-18 Nanopass Ltd. Microneedle structure and production method therefor
NZ525294A (en) 2000-10-13 2005-02-25 Alza Corp Apparatus and method for piercing skin with microprotrusions
US6821281B2 (en) * 2000-10-16 2004-11-23 The Procter & Gamble Company Microstructures for treating and conditioning skin
US7131987B2 (en) * 2000-10-16 2006-11-07 Corium International, Inc. Microstructures and method for treating and conditioning skin which cause less irritation during exfoliation
US6638246B1 (en) * 2000-11-28 2003-10-28 Scimed Life Systems, Inc. Medical device for delivery of a biologically active material to a lumen
EP1342075B1 (en) 2000-12-11 2008-09-10 President And Fellows Of Harvard College Device contaning nanosensors for detecting an analyte and its method of manufacture
DE10105549A1 (en) * 2001-02-06 2002-08-29 Roche Diagnostics Gmbh System for monitoring the concentration of analytes in body fluids
US6663820B2 (en) * 2001-03-14 2003-12-16 The Procter & Gamble Company Method of manufacturing microneedle structures using soft lithography and photolithography
US6721586B2 (en) * 2001-06-12 2004-04-13 Lifescan, Inc. Percutaneous biological fluid sampling and analyte measurement devices and methods
US7025774B2 (en) * 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
US6501976B1 (en) 2001-06-12 2002-12-31 Lifescan, Inc. Percutaneous biological fluid sampling and analyte measurement devices and methods
US6875613B2 (en) 2001-06-12 2005-04-05 Lifescan, Inc. Biological fluid constituent sampling and measurement devices and methods
US6793632B2 (en) 2001-06-12 2004-09-21 Lifescan, Inc. Percutaneous biological fluid constituent sampling and measurement devices and methods
US6767341B2 (en) * 2001-06-13 2004-07-27 Abbott Laboratories Microneedles for minimally invasive drug delivery
US6749792B2 (en) * 2001-07-09 2004-06-15 Lifescan, Inc. Micro-needles and methods of manufacture and use thereof
SE0102736D0 (en) * 2001-08-14 2001-08-14 Patrick Griss Side opened out-of-plane microneedles for microfluidic transdermal interfacing and fabrication process of side opened out-of-plane microneedles
US6881203B2 (en) * 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
CA2500452A1 (en) * 2001-09-28 2003-04-03 Biovalve Technologies, Inc. Switchable microneedle arrays and systems and methods relating to same
CA2500453A1 (en) 2001-09-28 2003-04-03 Biovalve Technologies, Inc. Microneedle with membrane
US6689100B2 (en) * 2001-10-05 2004-02-10 Becton, Dickinson And Company Microdevice and method of delivering or withdrawing a substance through the skin of an animal
US7399277B2 (en) * 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US20060228723A1 (en) 2002-01-16 2006-10-12 Keith Bradley System and method for electronic sensing of biomolecules
US7004928B2 (en) 2002-02-08 2006-02-28 Rosedale Medical, Inc. Autonomous, ambulatory analyte monitor or drug delivery device
US7955483B2 (en) 2002-03-18 2011-06-07 Honeywell International Inc. Carbon nanotube-based glucose sensor
US20030143113A2 (en) 2002-05-09 2003-07-31 Lifescan, Inc. Physiological sample collection devices and methods of using the same
KR101323980B1 (en) 2002-07-19 2013-10-30 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Microneedle device, method of using microneedle device and method of delivering microneedle device
US20040106904A1 (en) 2002-10-07 2004-06-03 Gonnelli Robert R. Microneedle array patch
DK1575656T3 (en) 2002-10-11 2009-09-14 Becton Dickinson Co Insulin delivery system with sensor
US6702790B1 (en) 2002-10-31 2004-03-09 Chauncey F. Ross Hypodermic needle
US20040200734A1 (en) 2002-12-19 2004-10-14 Co Man Sung Nanotube-based sensors for biomolecules
US6962772B2 (en) * 2002-12-27 2005-11-08 Industrial Technology Research Inst. Method for manufacturing 3-D high aspect-ratio microneedle array device
US7578954B2 (en) 2003-02-24 2009-08-25 Corium International, Inc. Method for manufacturing microstructures having multiple microelements with through-holes
US20060025717A1 (en) 2003-04-18 2006-02-02 The Regents Of The University Of California Method for forming hollow out-of-plane microneedles and devices formed hereby
US7415299B2 (en) * 2003-04-18 2008-08-19 The Regents Of The University Of California Monitoring method and/or apparatus
US7524464B2 (en) 2003-09-26 2009-04-28 Ahn Chong H Smart disposable plastic lab-on-a-chip for point-of-care testing
DE602004028649D1 (en) 2003-11-13 2010-09-23 Medtronic Minimed Inc LONG-TERM ARRANGEMENT ANALYTENSENSOR
EP1713533A4 (en) 2003-11-21 2008-01-23 Univ California Method and/or apparatus for puncturing a surface for extraction, in situ analysis, and/or substance delivery using microneedles
WO2005066360A1 (en) 2003-12-05 2005-07-21 Northwestern University Micro/nano-fabricated glucose sensors using single-walled carbon nanotubes
US20060258920A1 (en) 2004-04-14 2006-11-16 Oculir, Inc. Non-Invasive Analyte Measurement Glasses and Method of Use
US7076987B2 (en) 2004-08-05 2006-07-18 Becton, Dickinson And Company Method of producing tapered or pointed cannula
US20060058602A1 (en) 2004-08-17 2006-03-16 Kwiatkowski Krzysztof C Interstitial fluid analyzer
US7316665B2 (en) * 2004-08-25 2008-01-08 Becton, Dickinson And Company Method and device for the delivery of a substance including a covering
CA2602259A1 (en) 2005-03-29 2006-10-05 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
US20070004989A1 (en) 2005-06-29 2007-01-04 Parvinder Dhillon Device for transdermal sampling
US20070066934A1 (en) 2005-09-19 2007-03-22 Transport Pharmaceuticals, Inc. Electrokinetic delivery system and methods therefor
US20080154107A1 (en) 2006-12-20 2008-06-26 Jina Arvind N Device, systems, methods and tools for continuous glucose monitoring
US20090131778A1 (en) 2006-03-28 2009-05-21 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US20100049021A1 (en) 2006-03-28 2010-02-25 Jina Arvind N Devices, systems, methods and tools for continuous analyte monitoring
US20080058726A1 (en) 2006-08-30 2008-03-06 Arvind Jina Methods and Apparatus Incorporating a Surface Penetration Device
US20080234562A1 (en) 2007-03-19 2008-09-25 Jina Arvind N Continuous analyte monitor with multi-point self-calibration
US20080312518A1 (en) 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
US20090099427A1 (en) 2007-10-12 2009-04-16 Arkal Medical, Inc. Microneedle array with diverse needle configurations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027179A1 (en) 1998-03-13 2005-02-03 Cygnus, Inc. Biosensor and methods of use thereof
US6652478B1 (en) 1999-06-09 2003-11-25 The Procter & Gamble Company Intracutaneous edged microneedle apparatus
US20040096959A1 (en) 2000-12-19 2004-05-20 Matthias Stiene Analyte measurement
US20030143746A1 (en) 2002-01-31 2003-07-31 Sage Burton H. Self-calibrating body anayte monitoring system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1869414A4

Cited By (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066694B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066697B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10478108B2 (en) 1998-04-30 2019-11-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9042953B2 (en) 1998-04-30 2015-05-26 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9610034B2 (en) 2001-01-02 2017-04-04 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9937298B2 (en) 2001-06-12 2018-04-10 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US9802007B2 (en) 2001-06-12 2017-10-31 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9804114B2 (en) 2001-07-27 2017-10-31 Dexcom, Inc. Sensor head for use with implantable devices
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9907502B2 (en) 2002-04-19 2018-03-06 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9498160B2 (en) 2002-04-19 2016-11-22 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9186468B2 (en) 2002-04-19 2015-11-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US10034628B2 (en) 2003-06-11 2018-07-31 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US9895089B2 (en) 2003-08-01 2018-02-20 Dexcom, Inc. System and methods for processing analyte sensor data
US10786185B2 (en) 2003-08-01 2020-09-29 Dexcom, Inc. System and methods for processing analyte sensor data
US9649069B2 (en) 2003-08-22 2017-05-16 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11589823B2 (en) 2003-08-22 2023-02-28 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9750460B2 (en) 2003-08-22 2017-09-05 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9724045B1 (en) 2003-08-22 2017-08-08 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US11559260B2 (en) 2003-08-22 2023-01-24 Dexcom, Inc. Systems and methods for processing analyte sensor data
US11564602B2 (en) 2003-11-19 2023-01-31 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US11020031B1 (en) 2003-12-05 2021-06-01 Dexcom, Inc. Analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10188333B2 (en) 2003-12-05 2019-01-29 Dexcom, Inc. Calibration techniques for a continuous analyte sensor
US10299712B2 (en) 2003-12-05 2019-05-28 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11000215B1 (en) 2003-12-05 2021-05-11 Dexcom, Inc. Analyte sensor
US10898113B2 (en) 2003-12-09 2021-01-26 Dexcom, Inc. Signal processing for continuous analyte sensor
US9750441B2 (en) 2003-12-09 2017-09-05 Dexcom, Inc. Signal processing for continuous analyte sensor
US11638541B2 (en) 2003-12-09 2023-05-02 Dexconi, Inc. Signal processing for continuous analyte sensor
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US9050413B2 (en) 2004-02-26 2015-06-09 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US10966609B2 (en) 2004-02-26 2021-04-06 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US11246990B2 (en) 2004-02-26 2022-02-15 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US10835672B2 (en) 2004-02-26 2020-11-17 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9814414B2 (en) 2004-07-13 2017-11-14 Dexcom, Inc. Transcutaneous analyte sensor
US10314525B2 (en) 2004-07-13 2019-06-11 Dexcom, Inc. Analyte sensor
US11026605B1 (en) 2004-07-13 2021-06-08 Dexcom, Inc. Analyte sensor
US11045120B2 (en) 2004-07-13 2021-06-29 Dexcom, Inc. Analyte sensor
US9833176B2 (en) 2004-07-13 2017-12-05 Dexcom, Inc. Transcutaneous analyte sensor
US10722152B2 (en) 2004-07-13 2020-07-28 Dexcom, Inc. Analyte sensor
US10709362B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US11064917B2 (en) 2004-07-13 2021-07-20 Dexcom, Inc. Analyte sensor
US10993641B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US9668677B2 (en) 2004-07-13 2017-06-06 Dexcom, Inc. Analyte sensor
US10993642B2 (en) 2004-07-13 2021-05-04 Dexcom, Inc. Analyte sensor
US9610031B2 (en) 2004-07-13 2017-04-04 Dexcom, Inc. Transcutaneous analyte sensor
US10709363B2 (en) 2004-07-13 2020-07-14 Dexcom, Inc. Analyte sensor
US10799158B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US9986942B2 (en) 2004-07-13 2018-06-05 Dexcom, Inc. Analyte sensor
US10022078B2 (en) 2004-07-13 2018-07-17 Dexcom, Inc. Analyte sensor
US9078626B2 (en) 2004-07-13 2015-07-14 Dexcom, Inc. Transcutaneous analyte sensor
US10980452B2 (en) 2004-07-13 2021-04-20 Dexcom, Inc. Analyte sensor
US9060742B2 (en) 2004-07-13 2015-06-23 Dexcom, Inc. Transcutaneous analyte sensor
US10932700B2 (en) 2004-07-13 2021-03-02 Dexcom, Inc. Analyte sensor
US9055901B2 (en) 2004-07-13 2015-06-16 Dexcom, Inc. Transcutaneous analyte sensor
US10799159B2 (en) 2004-07-13 2020-10-13 Dexcom, Inc. Analyte sensor
US10918315B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10813576B2 (en) 2004-07-13 2020-10-27 Dexcom, Inc. Analyte sensor
US10827956B2 (en) 2004-07-13 2020-11-10 Dexcom, Inc. Analyte sensor
US10918314B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US11883164B2 (en) 2004-07-13 2024-01-30 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9044199B2 (en) 2004-07-13 2015-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US9801572B2 (en) 2004-07-13 2017-10-31 Dexcom, Inc. Transcutaneous analyte sensor
US10918313B2 (en) 2004-07-13 2021-02-16 Dexcom, Inc. Analyte sensor
US10524703B2 (en) 2004-07-13 2020-01-07 Dexcom, Inc. Transcutaneous analyte sensor
US10617336B2 (en) 2005-03-10 2020-04-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10716498B2 (en) 2005-03-10 2020-07-21 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10898114B2 (en) 2005-03-10 2021-01-26 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10856787B2 (en) 2005-03-10 2020-12-08 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918318B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918317B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610102B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. Transcutaneous analyte sensor
US10610136B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10918316B2 (en) 2005-03-10 2021-02-16 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610135B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10743801B2 (en) 2005-03-10 2020-08-18 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11000213B2 (en) 2005-03-10 2021-05-11 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10610137B2 (en) 2005-03-10 2020-04-07 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10624539B2 (en) 2005-03-10 2020-04-21 Dexcom, Inc. Transcutaneous analyte sensor
US10709364B2 (en) 2005-03-10 2020-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US10925524B2 (en) 2005-03-10 2021-02-23 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9078608B2 (en) 2005-03-10 2015-07-14 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9918668B2 (en) 2005-03-10 2018-03-20 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US11051726B2 (en) 2005-03-10 2021-07-06 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US8280476B2 (en) 2005-03-29 2012-10-02 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
US7949382B2 (en) 2005-03-29 2011-05-24 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
US10709332B2 (en) 2005-06-21 2020-07-14 Dexcom, Inc. Transcutaneous analyte sensor
US10813577B2 (en) 2005-06-21 2020-10-27 Dexcom, Inc. Analyte sensor
US10610103B2 (en) 2005-06-21 2020-04-07 Dexcom, Inc. Transcutaneous analyte sensor
US10952652B2 (en) 2005-11-01 2021-03-23 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11911151B1 (en) 2005-11-01 2024-02-27 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11399748B2 (en) 2005-11-01 2022-08-02 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11363975B2 (en) 2005-11-01 2022-06-21 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11272867B2 (en) 2005-11-01 2022-03-15 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9078607B2 (en) 2005-11-01 2015-07-14 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US11103165B2 (en) 2005-11-01 2021-08-31 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10201301B2 (en) 2005-11-01 2019-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10231654B2 (en) 2005-11-01 2019-03-19 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US10265000B2 (en) 2006-01-17 2019-04-23 Dexcom, Inc. Low oxygen in vivo analyte sensor
US11596332B2 (en) 2006-01-17 2023-03-07 Dexcom, Inc. Low oxygen in vivo analyte sensor
US11191458B2 (en) 2006-01-17 2021-12-07 Dexcom, Inc. Low oxygen in vivo analyte sensor
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US11432772B2 (en) 2006-08-02 2022-09-06 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US10349873B2 (en) 2006-10-04 2019-07-16 Dexcom, Inc. Analyte sensor
US11382539B2 (en) 2006-10-04 2022-07-12 Dexcom, Inc. Analyte sensor
US11399745B2 (en) 2006-10-04 2022-08-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US10136844B2 (en) 2006-10-04 2018-11-27 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1929941A1 (en) * 2006-12-07 2008-06-11 A. Menarini Industrie Farmaceutiche Riunite S.R.L. Portable device for the measurement and control of analytes in biological fluids
RU2470300C2 (en) * 2006-12-07 2012-12-20 А. Менарини Индустрие Фармачеутике Рьюните С.Р.Л. Portable device to measure and control analytes in biological liquids
US9741139B2 (en) 2007-06-08 2017-08-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US11373347B2 (en) 2007-06-08 2022-06-28 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US10403012B2 (en) 2007-06-08 2019-09-03 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
WO2008157255A1 (en) * 2007-06-14 2008-12-24 Arkal Medical, Inc. On-demand analyte monitor and method of use
US9668682B2 (en) 2007-09-13 2017-06-06 Dexcom, Inc. Transcutaneous analyte sensor
US11672422B2 (en) 2007-09-13 2023-06-13 Dexcom, Inc. Transcutaneous analyte sensor
US11160926B1 (en) 2007-10-09 2021-11-02 Dexcom, Inc. Pre-connected analyte sensors
US10653835B2 (en) 2007-10-09 2020-05-19 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US11744943B2 (en) 2007-10-09 2023-09-05 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
WO2009049243A3 (en) * 2007-10-12 2009-05-28 Arkal Medical Inc Microneedle array with diverse needle configurations
WO2009049243A2 (en) * 2007-10-12 2009-04-16 Arkal Medical, Inc. Microneedle array with diverse needle configurations
US11272869B2 (en) 2007-10-25 2022-03-15 Dexcom, Inc. Systems and methods for processing sensor data
US9717449B2 (en) 2007-10-25 2017-08-01 Dexcom, Inc. Systems and methods for processing sensor data
US10182751B2 (en) 2007-10-25 2019-01-22 Dexcom, Inc. Systems and methods for processing sensor data
US9901307B2 (en) 2007-12-17 2018-02-27 Dexcom, Inc. Systems and methods for processing sensor data
US10827980B2 (en) 2007-12-17 2020-11-10 Dexcom, Inc. Systems and methods for processing sensor data
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US10506982B2 (en) 2007-12-17 2019-12-17 Dexcom, Inc. Systems and methods for processing sensor data
US11342058B2 (en) 2007-12-17 2022-05-24 Dexcom, Inc. Systems and methods for processing sensor data
US11102306B2 (en) 2008-02-21 2021-08-24 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US10602968B2 (en) 2008-03-25 2020-03-31 Dexcom, Inc. Analyte sensor
US11896374B2 (en) 2008-03-25 2024-02-13 Dexcom, Inc. Analyte sensor
US10980461B2 (en) 2008-11-07 2021-04-20 Dexcom, Inc. Advanced analyte sensor calibration and error detection
US10675405B2 (en) 2009-03-27 2020-06-09 Dexcom, Inc. Methods and systems for simulating glucose response to simulated actions
US10610642B2 (en) 2009-03-27 2020-04-07 Dexcom, Inc. Methods and systems for promoting glucose management
US10537678B2 (en) 2009-03-27 2020-01-21 Dexcom, Inc. Methods and systems for promoting glucose management
US10835161B2 (en) 2009-09-30 2020-11-17 Dexcom, Inc. Transcutaneous analyte sensor
US10667733B2 (en) 2009-09-30 2020-06-02 Dexcom, Inc. Transcutaneous analyte sensor
US10165986B2 (en) 2010-02-12 2019-01-01 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US10278650B2 (en) 2010-02-12 2019-05-07 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US9833199B2 (en) 2010-02-12 2017-12-05 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US9041730B2 (en) 2010-02-12 2015-05-26 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US10265030B2 (en) 2010-02-12 2019-04-23 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US11769589B2 (en) 2010-02-12 2023-09-26 Dexcom, Inc. Receivers for analyzing and displaying sensor data
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
ES2353181A1 (en) * 2010-09-01 2011-02-28 Francisco Javie Garcia Saban Device for continuous measuring of an analyte
US10548525B2 (en) 2014-10-17 2020-02-04 Fitscript Llc Algorithms for diabetes exercise therapy
US11786175B2 (en) 2014-10-17 2023-10-17 Fitscript Llc Algorithms for diabetes exercise therapy
US9861310B2 (en) 2014-10-17 2018-01-09 Fitscript Llc Algorithms for diabetes exercise therapy
US11350862B2 (en) 2017-10-24 2022-06-07 Dexcom, Inc. Pre-connected analyte sensors
US11706876B2 (en) 2017-10-24 2023-07-18 Dexcom, Inc. Pre-connected analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
US11382540B2 (en) 2017-10-24 2022-07-12 Dexcom, Inc. Pre-connected analyte sensors
US11304632B2 (en) 2017-11-20 2022-04-19 Microjet Technology Co., Ltd. Blood glucose detection device
EP3485814A1 (en) * 2017-11-20 2019-05-22 Microjet Technology Co., Ltd Blood glucose detection device

Also Published As

Publication number Publication date
US20060219576A1 (en) 2006-10-05
WO2006105146A3 (en) 2007-11-15
EP1869414A4 (en) 2010-07-28
CA2602259A1 (en) 2006-10-05
US7949382B2 (en) 2011-05-24
US8280476B2 (en) 2012-10-02
EP1869414A2 (en) 2007-12-26
US20100292551A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
US8280476B2 (en) Devices, systems, methods and tools for continuous glucose monitoring
US20080234562A1 (en) Continuous analyte monitor with multi-point self-calibration
US20090131778A1 (en) Devices, systems, methods and tools for continuous glucose monitoring
US20100049021A1 (en) Devices, systems, methods and tools for continuous analyte monitoring
US20080154107A1 (en) Device, systems, methods and tools for continuous glucose monitoring
US20080312518A1 (en) On-demand analyte monitor and method of use
US20090099427A1 (en) Microneedle array with diverse needle configurations
JP3600158B2 (en) Monitoring physiological analytes
CA2543962C (en) Calibrating an analyte-measurement device
EP2514362A1 (en) Sensing fluid concentration for continuous glucose monitoring
US20170188898A1 (en) Devices and methods for enhanced skin perforation for continuous glucose monitoring
US20110257497A1 (en) Flux Enhancement in Continuous Glucose Monitoring
US20120172693A1 (en) Pump Arrangement in Continuous Analyte Monitoring
Eguílaz et al. Personal blood glucose analyzers
WO2018226245A1 (en) Devices and methods for enhanced skin perforation for continuous glucose monitoring

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2602259

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006748841

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU